Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effektivitet og sikkerhetsstudie av dovramilast hos personer med spedalsk type 2 -reaksjon

1. november 2026 oppdatert av: Medicines Development for Global Health

En 12-ukers, åpen, randomisert, standard for omsorgskontrollert, dosering av sikkerhet og effektivitetsstudie av dovramilast hos personer med moderat til alvorlig akutt eller tilbakevendende spedalskhet type 2-reaksjon

Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world. In this study, an experimental drug called dovramilast is being tested to see how it compares to current treatments for leprosy type 2 reaction. Specifically, this study aims to assess the efficacy of 100mg or 150 mg dovramilast compared with standard treatments (also known as standard of care). This study also aims to assess the safety of two strengths in adults with leprosy type 2 reaction.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

45

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Abomey-Calavi, Benin
        • Har ikke rekruttert ennå
        • Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli
      • Divo, Côte d’Ivoire
        • Har ikke rekruttert ennå
        • Chr de Divo
      • Manila, Filippinene
        • Rekruttering
        • Philippine General Hospital, University of the Philippines, Manila
        • Ta kontakt med:
    • Washington
      • Seattle, Washington, Forente stater, 98104
        • Rekruttering
        • Harborview Medical Center, University of Washington
        • Ta kontakt med:
          • Dr Jason Simmons, MD, PhD
          • Telefonnummer: 206-744-5463
          • E-post: jasonds@uw.edu
      • Yogyakarta, Indonesia
        • Rekruttering
        • Universitas Gadjah Mada
        • Ta kontakt med:
      • Tôlanaro, Madagaskar
        • Rekruttering
        • Programme national lutte contre la lèpre
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Aged 18 years of age or older.

  2. Provision of written informed consent.

  3. Laboratory confirmed previous or current Mycobacterium leprae or Mycobacterium lepromatosis infection.

  4. Leprosy type 2 reaction meeting the following criteria:

    • Either:

      i. Acute (first episode and no treatment initiated) or ii. Recurrent (at least one further episode occurring 28 days or more after withdrawal of leprosy type 2 reaction treatment).

    • Presence of at least 10 leprosy type 2 reaction tender papular and/or nodular skin lesions (not including scars).

    • An ENLIST score of at least 9.

  5. If a woman of reproductive potential, agree to the use of two reliable contraceptive measures (at least one of which is a highly effective form of contraception) from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care. Refer to Special Considerations for additional information.

  6. If male (including those who have had a successful vasectomy), agree to using a latex condom during any sexual contact with women of reproductive potential from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care.

Exclusion Criteria:

  1. Chronic leprosy type 2 reaction, defined as the reaction occurring for 24 weeks or more during which a subject has required treatment either continuously or where any treatment free period had been < 28 days.

  2. Receipt of thalidomide, lenalidomide, pomalidomide, systemic corticosteroids, clofazimine (> 50 mg/day), apremilast or any other phosphodiesterase (PDE) 4 inhibitor, or immunosuppressive/immunomodulatory treatment within 28 days of Baseline.

  3. Receipt of an investigational agent within 28 days of Baseline or 5 half-lives of the investigational agent (whichever is longer).

  4. Leprosy type 2 reaction with orchitis, uveitis, iritis, or severe neuritis (Grade 3 or greater severe neuritis).

  5. Current diagnosis of leprosy type 1 reaction or Lucio's phenomenon.

  6. Current tuberculosis, malaria, cutaneous or visceral leishmaniasis or other serious bacterial, viral, or parasitic infection at Screening or Baseline.

  7. Active systemic fungal infection requiring or undergoing treatment.

  8. Other than leprosy type 2 reaction, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.

  9. Other than leprosy type 2 reaction, any other dermatological condition that could, in the opinion of the Investigator, interfere with the study assessments.

  10. Chronic hepatitis B, chronic hepatitis C, or human immunodeficiency virus (HIV) positive.

  11. Pregnant women or breastfeeding mothers.

  12. Use (or planned use) of antimetabolites or alkylating agents, rifampin use more frequent than monthly, phenobarbital, carbamazepine, phenytoin, traditional or herbal preparations (including St. John's wort), foods (including grapefruit) known to affect activity of the cytochrome (CYP)3A4 enzyme; of all strong CYP3A and P-gp inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, ritonavir, cobicistat, diltiazem; and sensitive substrates of CYP3A4, CYP2C9, CYP2C19, and P-gp. Other CYP3A4, CYP2C9, CYP2C19, and P-gp non-sensitive substrates should be used with caution when concomitantly administered with dovramilast.

  13. Known or suspected active substance abuse or a history of substance abuse within 6 months prior to Screening.

  14. Prior history of suicide attempt at any time in the subject's lifetime prior to Screening or Randomization, or major psychiatric illness requiring hospitalization within the last 3 years.

  15. Current diagnosis of depression, and/or history of suicide ideation

  16. History of or presence of cardiac disease, including:

    • Clinically significant abnormal electrocardiogram
    • QTcF > 450 msec
  17. Receipt of a vaccination within 7 days of Baseline.

  18. Known or suspected hypersensitivity to: PDE4 inhibitors including dovramilast or apremilast; thalidomide; prednisolone, or; excipients used in the formulation of dovramilast, thalidomide or prednisolone.

  19. Body Mass Index < 15 kg/m^2 or > 35 kg/m^2.

  20. Unable to, or significant difficulty with, swallowing tablets/capsules.

  21. Anemia requiring transfusion.

  22. History of or current pancreatitis.

  23. Known or suspected cirrhosis of the liver.

  24. The following laboratory abnormalities:

    • White blood cells (WBC) < 2.5 x 10^9/ L.
    • Neutrophils (granulocytes) < 1.0 x 10^9/L.
    • Platelets < 80 x 10^9/L.
    • Aspartate aminotransferase or alanine aminotransferase > 2 times the upper limit of reference range.
    • Albumin < 30 mg/dL.
    • Bilirubin > 2 mg/dL
    • Calculated creatinine clearance (Cockcroft Gault) < 50 milliliter (mL)/minute.
    • Lipase ≥ 1.6 times the upper limit
  25. Previous participation in this study

  26. Unwilling, unlikely or unable to comply with all protocol specified assessments, including photographic assessments

  27. Enrolled in another leprosy type 2 reaction treatment study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Dovramilast 100 mg

Dovramilast

Eksperimentell: Dovramilast 150 mg

Dovramilast

Aktiv komparator: Standard of care

Prednisolone (or thalidomide US sites only)

Standard of care

Standard of care (US only)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The proportion of dovramilast (100 mg or 150 mg) recipients achieving a 75% improvement in leprosy type 2 reaction skin lesions at week 12
Tidsramme: 12 weeks

The proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count of at least 75% from Baseline at Week 12 without the need for rescue.

Rescue is defined as:

  1. A change from dovramilast at any dose to standard of care or dose maintenance beyond taper time points defined in standard of care treatment guidelines (and specified in this protocol), or
  2. Standard of care dose increase, switching to or adding another leprosy type 2 reaction treatment
12 weeks
Incidence and severity of adverse events
Tidsramme: 12 weeks

The incidence and severity of adverse events, changes in vital signs and blood dyscrasias

12 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Endring fra baselinevering (Erythema Nodosum LeProsum International Study) Severity Scale Score
Tidsramme: Ved hvert post -baseline -tidspunkt
Ved hvert post -baseline -tidspunkt
Endringer i nevropati fra baseline -karakteren
Tidsramme: 12 uker
12 uker
Andel fag som krever redningsmedisiner og tid til å starte redningsmedisiner
Tidsramme: 12 uker
12 uker
Total mengde behandling for spedalskhetstype 2 -reaksjon administrert
Tidsramme: 12 uker
12 uker
Resolution of fever to ≤ Grade 1
Tidsramme: 12 weeks

Proportion of subjects with resolution of fever to ≤ Grade 1 among the subgroup of subjects with fever present at Baseline at Grade 2 or greater.

12 weeks
Skin lesion count changes
Tidsramme: 12 weeks

• Change from Baseline in skin lesion count up to and including Week 12.

12 weeks
Change from Baseline of each of the following parameters when present at Baseline at Grade 2 or greater
Tidsramme: from baseline to Week 12
  • Leprosy type 2 reaction lesions with respect to: number, inflammation, and extent
  • Neuritis
  • Pain:
  • Fever
  • Peripheral edema with respect to location and severity
  • Inflammation of joints and/or digits
  • Lymphadenopathy
from baseline to Week 12
Time to resolution
Tidsramme: 12 weeks

For each individual leprosy type 2 reaction when present at least Grade 1 at Baseline

12 weeks
Recurrences
Tidsramme: 48 weeks

Recurrence is defined as new signs and symptoms consistent with leprosy type 2 reaction. The number of Recurrence episodes requiring treatment.

48 weeks
Exposure metrics of dovramilast
Tidsramme: 48 weeks

Area under the curve (AUC)

48 weeks
Exposure metrics of the dovramilast metabolite M15
Tidsramme: 48 weeks

Area under the curve (AUC)

48 weeks
Skin lesion count changes
Tidsramme: 12 weeks

• Proportion of Responders at each post-Baseline timepoint.

12 weeks
Skin lesion count changes
Tidsramme: 12 weeks

Proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count from Baseline of 50%, 90% and 100% without Rescue at Week 12.

12 weeks
Exposure metrics of dovramilast
Tidsramme: 48 weeks

Including AUC, Cmax, and Tmax.

48 weeks
Exposure metrics of dovramilast
Tidsramme: 48 weeks

Cmax

48 weeks
Exposure metrics of dovramilast
Tidsramme: 48 weeks

Tmax.

48 weeks

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Quantification of immunological markers in whole blood samples by central laboratory, blinded to patient identification, treatment arm, and study visit
Tidsramme: 48 weeks

Concentration of inflammatory cytokines

48 weeks
Quantification of immunological markers in skin biopsies by central laboratory, blinded to patient identification, treatment arm, and study visit
Tidsramme: 48 weeks

Leukocyte infiltration of skin lesions by histology

48 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. oktober 2026

Primær fullføring (Antatt)

1. januar 2027

Studiet fullført (Antatt)

1. juli 2028

Datoer for studieregistrering

Først innsendt

7. august 2025

Først innsendt som oppfylte QC-kriteriene

7. september 2025

Først lagt ut (Faktiske)

15. september 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

1. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere